Platinum exposure and cause-specific mortality among patients with testicular cancer

Autor: Ronald de Wit, Sjoukje Lubberts, Michael Schaapveld, O. W. M. Meijer, Simon Horenblas, Igle J. de Jong, Tineke J. Smilde, Alexandra W. van den Belt-Dusebout, Jourik A. Gietema, Hetty A van den Berg, Ben G. L. Vanneste, Gerard Groenewegen, Maarten C.C.M. Hulshof, Maureen J.B. Aarts, Harmke J. Groot, Katarzyna Jóźwiak, Philip Poortmans, J. Alfred Witjes, Flora E. van Leeuwen
Přispěvatelé: Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Radiation Oncology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Radiotherapy, CCA - Cancer Treatment and Quality of Life, Medical Oncology
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Cancer Research
medicine.medical_treatment
cause‐specific mortality
cisplatin
Gastroenterology
Cohort Studies
0302 clinical medicine
GERM-CELL CANCER
Risk Factors
Cause of Death
Epidemiology
030212 general & internal medicine
platinum
RISK
education.field_of_study
Mortality rate
THROMBOEMBOLIC EVENTS
Hazard ratio
LONG-TERM SURVIVORS
Neoplasms
Second Primary
Middle Aged
CHEMOTHERAPY
Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
testicular cancer
Oncology
CARDIOVASCULAR-DISEASE
030220 oncology & carcinogenesis
Cohort
Original Article
Female
epidemiology
Adult
medicine.medical_specialty
cause-specific mortality
Population
Antineoplastic Agents
Discipline
Young Adult
03 medical and health sciences
Testicular Neoplasms
SDG 3 - Good Health and Well-being
Internal medicine
Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]
medicine
Humans
2ND CANCERS
education
Testicular cancer
Proportional Hazards Models
Chemotherapy
Bladder cancer
CHILDHOOD-CANCER
business.industry
Original Articles
medicine.disease
MYOCARDIAL-INFARCTION
business
survivorship
Zdroj: Cancer, 126(3), 628-639. Wiley
Cancer, 126(3), 628-639. John Wiley and Sons Inc.
Cancer, 126, 628-639
Groot, H J, van Leeuwen, F E, Lubberts, S, Horenblas, S, de Wit, R, Witjes, J A, Groenewegen, G, Poortmans, P M, Hulshof, M C C M, Meijer, O W M, de Jong, I J, van den Berg, H A, Smilde, T J, Vanneste, B G L, Aarts, M J B, Jóźwiak, K, van den Belt-Dusebout, A W, Gietema, J A & Schaapveld, M 2020, ' Platinum exposure and cause-specific mortality among patients with testicular cancer ', Cancer, vol. 126, no. 3, pp. 628-639 . https://doi.org/10.1002/cncr.32538
Cancer, 126(3), 628. John Wiley and Sons Inc.
Cancer, 126, 3, pp. 628-639
Cancer, 126, 628-639. John Wiley & Sons Inc.
Cancer
ISSN: 0008-543X
Popis: Background Although testicular cancer (TC) treatment has been associated with severe late morbidities, including second malignant neoplasms (SMNs) and ischemic heart disease (IHD), cause‐specific excess mortality has been rarely studied among patients treated in the platinum era. Methods In a large, multicenter cohort including 6042 patients with TC treated between 1976 and 2006, cause‐specific mortality was compared with general population mortality rates. Associations with treatment were assessed with proportional hazards analysis. Results With a median follow‐up of 17.6 years, 800 patients died; 40.3% of these patients died because of TC. The cumulative mortality was 9.6% (95% confidence interval [CI], 8.5%‐10.7%) 25 years after TC treatment. In comparison with general population mortality rates, patients with nonseminoma experienced 2.0 to 11.6 times elevated mortality from lung, stomach, pancreatic, rectal, and kidney cancers, soft‐tissue sarcomas, and leukemia; 1.9‐fold increased mortality (95% CI, 1.3‐2.8) from IHD; and 3.9‐fold increased mortality (95% CI, 1.5‐8.4) from pneumonia. Seminoma patients experienced 2.5 to 4.6 times increased mortality from stomach, pancreatic, bladder cancer and leukemia. Radiotherapy and chemotherapy were associated with 2.1 (95% CI, 1.8‐2.5) and 2.5 times higher SMN mortality (95% CI, 2.0‐3.1), respectively, in comparison with the general population. In a multivariable analysis, patients treated with platinum‐containing chemotherapy had a 2.5‐fold increased hazard ratio (HR; 95% CI, 1.8‐3.5) for SMN mortality in comparison with patients without platinum‐containing chemotherapy. The HR for SMN mortality increased 0.29 (95% CI, 0.19‐0.39) per 100 mg/m2 platinum dose administered (P trend
Platinum‐containing chemotherapy is associated with a dose‐dependent increase in the risk of cancer mortality among patients with testicular cancer. Patients with testicular cancer experience increased mortality from second malignancies as well as causes other than cancer, particularly ischemic heart diseases.
Databáze: OpenAIRE
Externí odkaz: